Thromboangiitis obliterans (Buerger's disease) - a review
DOI:
https://doi.org/10.12775/JEHS.2023.36.01.012Keywords
Thromboangiitis obliterans, Buerger's disease, Thromboangitis diagnosis, Thromboangitis treatmentAbstract
Introduction: Thromboangiitis obliterans (Buerger's disease) is a segmental, multilocular, nonatherosclerotic inflammatory disease that most commonly affects small and medium sized arteries, veins and nerves of the extremities. The disease is spread worldwide and mainly affects young male tobacco smokers.
Aim of study: In this review we gather and summarize available knowledge about pathogenesis, diagnosis and methods of treatment of Thromboangiitis obliterans.
Methods and materials: Search of the articles in PubMed and GoogleScholar databases was performed using following keywords: Thromboangitis obliterans; Buerger's disease; Thromboangitis Obliterans pathogenesis; Thromboangitis Obliterans diagnosis; Thromboangitis Obliterans treatment; Thromboangitis Obliterans pathophysiology; Thromboangitis Obliterans symptoms; Thromboangitis Obliterans epidemiology; Thromboangitis Obliterans risk factors; The most relevant to the topic articles were included.
Summary: Even though the causes of the disease remain unclear and treatment is still difficult, there are new experimental methods of treatment being researched that may bring a breakthrough in the future.
References
v. Winiwarter F. Ueber eine eigenthümliche Form von Endarteriitis und Endophlebitis mit Gangrän des Fußes. Arch Klin Chir 1879; 23: 202 – 226
BUERGER, L. (1973). Thrombo-angiitis obliterans: a study of the vascular lesions leading to presenile spontaneous gangrene. The American Journal of the Medical Sciences, 266(4), 278–291.
Olin, J. W. (2000). Thromboangiitis Obliterans (Buerger’s Disease). New England Journal of Medicine, 343(12), 864–869.
Piazza, G., & Creager, M. A. (2010). Thromboangiitis Obliterans. Circulation, 121(16), 1858–1861.
Klein-Weigel, P. F., & Richter, J. G. (2014). Thromboangiitis obliterans (Buergers disease). Vasa, 43(5), 337–346.
Olin JW, Young JR, Graor RA, Ruschhaupt WF, Bartholomew JR: The changing clinical spectrum of thromboangiitis obliterans (Buerger's disease). Circulation 1990, 82:IV3-8.
Adar, R., Papa, M. Z., Halpern, Z., Mozes, M., Shoshan, S., Sofer, B., … Mozes, E. (1983). Cellular Sensitivity to Collagen in Thromboangiitis Obliterans. New England Journal of Medicine, 308(19), 1113–1116.
Eichhorn J, Sima D, Lindschau C, Turowski A, Schmidt H, Schneider W, Haller H, Luft FC. Antiendothelial cell antibodies in thromboangiitis obliterans. Am J Med Sci. 1998; 315:17–23.
Makita S, Nakamura M, Murakami H, Komoda K, Kawazoe K, Hiramori K. Impaired endothelium-dependent vasorelaxation in peripheral vasculature of patients with thromboangiitis obliterans (Buerger’s disease). Circulation 1996;94:Suppl II:II-211–II-215.
Lie JT. Diagnostic histopathology of major systemic and pulmonary vasculitic syndromes. Rheum Dis Clin North Am 1990;16:269-92.
Leu, H. J. (1975). Early Inflammatory Changes in Thromboangiitis obliterans. Pathobiology, 43(2-3), 151–156. doi:10.1159/000162812
Williams, G. (1969). Recent views on Buerger’s disease. Journal of Clinical Pathology, 22(5), 573–578. doi:10.1136/jcp.22.5.573
Mills, J. L. (2003). Buerger’s disease in the 21st century: diagnosis, clinical features, and therapy. Seminars in Vascular Surgery, 16(3), 179–189. doi:10.1016/s0895-7967(03)00023-1
Sasaki, S., Sakuma, M., Kunihara, T., & Yasuda, K. (1999). Current trends in thromboangiitis obliterans (buerger’s disease) in women. The American Journal of Surgery, 177(4), 316–320. doi:10.1016/s0002-9610(99)00046-x
Hida, N., & Ohta, T. (2013). Current Status of Patients with Buerger Disease in Japan. Annals of Vascular Diseases, 6(3), 617–623. doi:10.3400/avd.oa.13-00012
Lie, J. T. (1989). The Rise and Fall and Resurgence of Thromboangiitis Obliterans (Buerger’s Disease). Pathology International, 39(3), 153–158. doi:10.1111/j.1440-1827.1989.tb01494.x
Arkkila, P. E. (2006). Orphanet Journal of Rare Diseases, 1(1), 14. doi:10.1186/1750-1172-1-14
McKusick, V. A. (1962). Buerger’s Disease: A Distinct Clinical and Pathologic Entity. JAMA: The Journal of the American Medical Association, 181(1), 5. doi:10.1001/jama.1962.03050270007002
ALLEN, E. V. (1929). THROMBOANGIITIS OBLITERANS. The American Journal of the Medical Sciences, 178(2), 237–243. doi:10.1097/00000441-192908000-00009
Mills JL, Porter JM. Buerger’s disease: a review and update. Semin Vasc Surg 1993;6:14-23.
Papa, M. Z., Rabi, I., & Adar, R. (1996). A point scoring system for the clinical diagnosis of B uerger’s disease. European Journal of Vascular and Endovascular Surgery, 11(3), 335–339. doi:10.1016/s1078-5884(96)80081-5
Shionoya, S. (1983). What is Buerger’s disease? World Journal of Surgery, 7(4), 544–551. doi:10.1007/bf01655948
Corelli F. Buerger’s disease: cigarette smoker disease may always be cured by medical therapy alone: uselessness of operative treatment. J Cardiovasc Surg (Torino) 1973;14:28-36
Gifford RW Jr, Hines EA Jr. Complete clinical remission in thromboangiitis obliterans during abstinence from tobacco: report of case. Proc Staff Meetings Mayo Clinic 1951;26:241-5
Fiessinger, J. N., & Schäfer, M. (1990). Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliterans. The Lancet, 335(8689), 555–557. doi:10.1016/0140-6736(90)90346-7
Hussein EA, el Dorri A. Intra-arterial streptokinase as adjuvant therapy for complicated Buerger’s disease: early trials. Int Surg 1993;78:54-8.
Kubota, Y., Kichikawa, K., Uchida, H., Nishimine, K., Hirohashi, R., & Ohishi, H. (1997). Superselective Urokinase Infusion Therapy for Dorsalis Pedis Artery Occlusion in Buerger’s Disease. CardioVascular and Interventional Radiology, 20(5), 380–382. doi:10.1007/s002709900172
Chander J, Singh L, Lal P, Jain A, Lal P, Ramteke VK: Retroperitoneoscopic lumbar sympathectomy for buerger's disease: a novel technique. JSLS 2004, 8:291-296.
Benoit, E., O’donnell, T. F., & Patel, A. N. (2013). Safety and Efficacy of Autologous Cell Therapy in Critical Limb Ischemia: A Systematic Review. Cell Transplantation, 22(3), 545–562. doi:10.3727/096368912x636777
Boda, Z., Udvardy, M., Rázsó, K., Farkas, K., Tóth, J., Jámbor, L., … Rajnavölgyi, E. (2008). Stem Cell Therapy: A Promising and Prospective Approach in the Treatment of Patients With Severe Buerger’s Disease. Clinical and Applied Thrombosis/Hemostasis, 15(5), 552–560. doi:10.1177/1076029608319882
Durdu, S., Akar, A. R., Arat, M., Sancak, T., Eren, N. T., & Ozyurda, U. (2006). Autologous bone-marrow mononuclear cell implantation for patients with Rutherford grade II-III thromboangiitis obliterans. Journal of Vascular Surgery, 44(4), 732–739. doi:10.1016/j.jvs.2006.06.023
Teraa, M., Sprengers, R. W., van der Graaf, Y., Peters, C. E. J., Moll, F. L., & Verhaar, M. C. (2013). Autologous Bone Marrow–Derived Cell Therapy in Patients With Critical Limb Ischemia. Annals of Surgery, 258(6), 922–929. doi:10.1097/sla.0b013e3182854cf1
Todoli Parra, J. A., Hernández, M. M., & Arrébola López, M. A. (2010). Efficacy of Bosentan in Digital Ischemic Ulcers. Annals of Vascular Surgery, 24(5), 690.e1–690.e4. doi:10.1016/j.avsg.2010.03.011
De Haro, J., Acin, F., Bleda, S., Varela, C., & Esparza, L. (2012). Treatment of thromboangiitis obliterans (Buerger’s disease) with bosentan. BMC Cardiovascular Disorders, 12(1). doi:10.1186/1471-2261-12-5
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Rafał Bogacz, Magdalena Gaik, Ewa Uram, Inga Magda, Justyna Woźniak, Karol Womperski, Magdalena Osuch
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 354
Number of citations: 0
